3Modi NB, Eppler S, Breed J, et al. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction[J]. Thromb Haemost, 1998,79:134
4Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial[J]. Circulation, 1998,98:2805
5De Lemos JA, Antman EM, Giugliano RP. Comparison of a 60-versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarc-tion[J]. Am J Cardiol, 2000,86:1235
6Roe MT, Ohman EM, Maas ACP, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion[J]. J Am Coll Cardiol, 2001,37:9
7Gurwitz JH, Gore JM, Goldberg R J, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction: participants in the National Registry of Myocardial Infarction 2[J]. Ann Intern Med, 1998,129:597
8Trial of abciximab with and without low-dose reteplase for acute myocardial infarction: strategies for Patency Enhancement in the Emergency Department (SPEED) Group[J]. Circulation,2000,101:2788
9The COBALT Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction[J]. N Engl J Med, 1997,337:1124
10Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients[J]. JAMA, 2000,277:307
